Cancer
Conditions
Keywords
Antidiabetic agents, risk of cancer, Type 2 diabetes mellitus
Brief summary
A retrospective analysis was conducted based on data of the National Health Insurance Fund in Hungary. Overall cancer risk and site-specific cancer risks were analysed in a target trial emulation design when comparing all available antidiabetic therapies to MET and monotherapies and primary combination therapies against each other. The model used in the analysis was corrected for age, gender, co-morbidities, selected cardiovascular medications and inpatient and outpatient visits.
Interventions
DRUGMetformin
Metformin monotherapy
DRUGsulphonylurea
SU monotherapy
DRUGDPP-4 inhibitor
DPP-4 inhibitor monotherapy
GLP-1 Receptor Agonist monotherapy
DRUGSGLT-2 inhibitor
SGLT-2 inhibitor monotherapy
DRUGinsulin
Insulin monotherapy
DRUGMET + SU
MET + SU combination
DRUGMET + DPP-4 inhibitor
MET + DPP-4 inhibitor combination
DRUGMET + GLP-1RA
MET + GLP-1RA combination
DRUGMET + SGLT2i
MET + SGLT2i combination
DRUGMET + INS
MET + insulin combination
Sponsors
University of Pecs
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
19 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Type 2 diabetes mellitus * Antidiabetic medication initiators
Exclusion criteria
* Antidiabetic prescription in the previous 5 years * Recent pancreatectomy (previous or subsequent 90 days after inclusion)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall cancer risk | 2016-2022 |
Countries
Hungary
Contacts
STUDY_CHAIRGyörgy Rokszin, M.D., Ph.D.
Outcome results
None listed